

Journal Pre-proof

Developing Core Outcome Sets for Vascular Conditions Across Europe, Not As Easy As It Sounds

Matthew Machin, Janet T. Powell

PII: S2666-688X(22)00055-7

DOI: <https://doi.org/10.1016/j.ejvsvf.2022.11.003>

Reference: EJVSVF 1002

To appear in: *EJVES Vascular Forum*


Received Date: 28 October 2022

Accepted Date: 15 November 2022

Please cite this article as: Machin M, Powell JT, Developing Core Outcome Sets for Vascular Conditions Across Europe, Not As Easy As It Sounds, *EJVES Vascular Forum* (2022), doi: <https://doi.org/10.1016/j.ejvsvf.2022.11.003>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.



1 HIGHLIGHTS

- 2 • Clinical outcome measures are largely chosen by clinicians rather than patients
- 3 • Core outcome sets can improve representation in studies for all key stakeholders
- 4 • The report outlines methods and challenges of conducting European core outcome
- 5 sets
- 6 • There are considerable barriers to developing European core outcome sets
- 7 • As a European vascular community, we should produce sets through collaboration

9 SHORT REPORT

10 Developing Core Outcome Sets for Vascular Conditions Across Europe, Not As Easy As It
11 Sounds

12
13 Matthew Machin* and Janet T. Powell

14
15 Department of Surgery & Cancer, Imperial College London, UK

16
17 Running title: Developing European COS

18
19 *Corresponding author. Department of Surgery & Cancer, Imperial College London, Charing
20 Cross Hospital, Fulham Palace Road, London, W6 8RF.

21 matthew.machin12@imperial.ac.uk (Matthew Machin)

22
23
24 **Introduction:** Most of the outcomes reported in the literature have been chosen by doctors,
25 constituting “traditional” outcome measures such as mortality and re-intervention. Some of
26 the key outcome measures important to patients, families, health providers and other
27 stakeholders may have been overlooked. Core outcome sets, consisting of 6 – 15 outcomes,
28 can improve representation of all key stakeholders, standardise outcome reporting, and
29 improve future ability to pool results. The aim of this study was to outline the methods and
30 challenges of conducting European core outcome sets.

31 **Report:** As an overview, development of core outcome sets follow a multi step iterative
32 process: (1) Systematic review of the literature summarising existing outcome measures, (2)
33 Focus group meeting with patients and other stakeholders to establish missing outcome
34 measures, (3) Development and piloting of Delphi survey, (4) Delphi consensus study for
35 prioritisation of outcomes and establishing consensus, and (5) European consensus meeting

36 to produce a core outcome set. The challenges include the varying ethical requirements for
37 survey work across Europe and translation for surveys and consensus meetings.

38 **Discussion:** There is an increasing need for core outcome sets to complement clinical
39 practice guidelines. As a European vascular community we need to produce these through
40 collaborative efforts. Unfortunately, there are considerable barriers to doing so – the time
41 and energy required to set up a core outcome study is not dissimilar to that of a multicentre
42 randomised trial. Currently only one core outcome set exists for vascular surgery, for critical
43 limb ischaemia, but this was developed in a single country.

44

45 **Keywords:** Clinical trial, Core outcome set, Patient reported outcome measures, Vascular
46 surgery

47

48

49 <H1>INTRODUCTION

50 As technology advances at an ever increasing pace, there is an increasing need to evaluate
51 the clinical effectiveness of these new treatments as rapidly and as cost effectively as
52 possible. This often means synthesising evidence from different observational studies or
53 randomised trials. Traditionally, vascular surgeons have focused on assessing parameters
54 such as mortality, complications, and time spent in hospital as detailed in a recent
55 systematic review of clinical studies investigating treatments for abdominal aortic aneurysm.¹
56 However, the patients themselves, their families, nurses and community medical staff may
57 value other outcomes more highly. To represent the needs of all stakeholders, particularly
58 patients, the concept of a “core outcome set” has been developed.

59 Core outcome sets have been developed in many areas of surgery but there is
60 currently only one core outcome set in vascular surgery, developed for studies assessing
61 treatments for those requiring amputation due to critical limb ischaemia.² This was
62 developed in the United Kingdom over several years as it followed the standard
63 methodology of systematic review, focus groups, and Delphi consensus survey. Given that
64 this core outcome set was developed in one outpost of Europe, there are questions over
65 whether it is applicable to the rest of mainland Europe. This report provides an overview of
66 developing core outcome sets which are widely applicable across Europe.

67 <H1>REPORT

68 <H2>Where to start?

69 The COMET handbook³ provides a source of advice about “how to do it” and keeps a
70 register of core outcome sets in progress/completed. In this sense, it is a parallel of the
71 PROSPERO registry for systematic reviews.⁴ On identification of a core outcome set in
72 progress, a researcher can ask to join the existing team rather than duplicate work.

73 As an overview, development of a core outcome set follows a multi step process:

- 74 • Systematic review summarising existing outcome measures.
- 75 • Focus group meeting with patients and other stakeholders to establish important
- 76 missing outcome measures.
- 77 • Development of Delphi survey with piloting and iteration.
- 78 • Delphi consensus study for prioritisation of outcomes and establishing consensus.
- 79 • European consensus meeting to produce a core outcome set.

80 <H2>**Systematic review to gather existing outcome measures**

81 The starting point for all core outcome sets is a systematic review of the outcomes reported
82 in the literature. Such reviews can yield thousands of references, so it is prudent to introduce
83 restrictions, including date and extracting prespecified outcomes only. Importantly, the
84 purpose of this systematic review differs to that of a conventional one. Rather than extract,
85 critique, and evaluate the evidence, its purpose is to assess the evolution of outcome
86 measures reported, compiling a register of these outcomes.

87 Many vascular studies report a limited number of primary and secondary outcomes
88 but also a multitude of others, while some studies do not prespecify any outcomes and
89 embark on a “fishing trip” to find out whether there are any associations or correlations of
90 interest. The best quality studies identify their main outcomes ahead of time and these are
91 the outcomes reported for almost all participants. Hence, focusing on prespecified outcomes
92 limits the work involved while improving outcome reporting. Often only retrieving studies
93 conducted in the last 10 – 20 years will limit the workload without compromising on quality.

94 Given the volume of references which need to be read and extracted, a team of
95 several reviewers may be needed with duplicate extraction limited to a random 10 – 20% of
96 papers checking for consistency. The present authors recommend having reviewers from
97 more than one country to reduce healthcare system effects and enable inclusion of multiple
98 languages.

99 Outcome measure, outcome timing, outcome definition, and completion rate are key
100 variables to extract. Timing of the outcome (e.g., in hospital, three years) is often overlooked;
101 however, these durations are important to include in the future consensus study.

102 <H2>**Focus group meetings with key stakeholders, mainly patients**

103 Additional input should be sought from focus groups of stakeholders as most of the literature
104 comes predominantly from clinicians and carries their view of important outcomes. Ideally,
105 focus groups should be take place across several European countries. Focus groups with
106 patients, their families, hospital managers or others to identify additional outcome measures
107 may not require ethical approval as the purpose is listening to improve the quality of care
108 rather than primary research. There are various resources on involving patients in research,

109 including the COMET handbook and guidance on the National Institute for Health and Care
110 Research website (although not specific to core outcome sets).⁵

111 The full list of outcomes, from the literature review in addition to others identified as
112 important by focus groups, should now be categorised according to a published taxonomy.
113 This aims to classify which, rather than how, outcomes are measured, for example, cognitive
114 functioning rather than “Montreal Cognitive Assessment”.⁶ These outcomes now need to be
115 prioritised by category and timing for inclusion as questions with Likert scale responses, for
116 the Delphi consensus phase.

117 **<H2>Ethical and institutional approval**

118 The need for formal ethical approval for focus groups and Delphi consensus studies varies
119 across Europe. For example, any study fulfilling the definition of research in the UK recruiting
120 from healthcare settings requires formal ethical approval issued by the Health Research
121 Authority (irrespective of whether the project is a survey).⁷ In some countries, such as the
122 Netherlands, survey work may be conducted under an ethical waiver, while in others ethical
123 approvals are not required. Individual institutional ethical approval and/or waiver can be
124 issued in some European centres. Considerable time (at least six months) should be allowed
125 for this prior to launching the Delphi consensus study.

126 **<H2>European Delphi consensus study**

127 The Delphi consensus study assesses the importance of all the identified outcome measures
128 across stakeholder groups. The COMET handbook³ offers advice on the set up of the
129 Delphi, including recommendations to avoid bias such as domain randomisation. The Delphi
130 should consist of domains of groups of similar outcomes with accompanying explanations
131 detailing the outcome measure.

132 The Delphi consensus study should be piloted across all the stakeholder groups and
133 across multiple countries in their respective (translated) languages. Troubleshooting is
134 undertaken to ensure that the platform and Delphi perform optimally. Inspection of the
135 results, for example, looking for bimodal distributions, is helpful to identify poorly performing
136 questions.

137 There are several online platforms that have been used to deliver Delphi consensus
138 studies, including DelphiManager, Qualtrics, and REDCap. An important consideration is the
139 level of security and insurance that providers offer and ensuring this complies with the study
140 sponsor’s requirements ahead of time. Pen and paper could be the most optimum method of
141 delivery depending on access and acceptability of online platforms.

142 There should be at least two rounds of Delphi survey, with the potential to include
143 additional rounds if required. Round 2 can be deployed in the same manner as round 1, or
144 outcomes can be removed to increase likelihood of consensus. Criteria for inclusion in round
145 2 vary in the literature with no standard methodology. Again, the COMET handbook³ sheds

146 light on potential methods. For example, one approach would be to include any item that is
147 rated 7 – 9 (on a 9 point Likert scale) by $\geq 50\%$ participants and 1 – 3 by $\leq 15\%$ of
148 participants in at least one stakeholder group.

149 <H2>European consensus meeting

150 The Delphi consensus study provides a breakdown of outcome prioritisation for each
151 stakeholder group. Although it is likely that consensus will be reached on most outcomes, it
152 is also likely that some measures will be held with high importance by a single group but lack
153 a majority. A consensus meeting consisting of stakeholder representatives allows a dialogue
154 to outline the rationale underpinning the Delphi results and finalisation of the core outcome
155 set. While such consensus meetings for clinicians and industry can be conducted in English,
156 trans-European consensus meetings of patients is a greater challenge and require
157 simultaneous translation resources for online meetings. Another way to approach this
158 problem might be for the European Society for Vascular Surgery (ESVS) to establish an
159 expert patient panel. The exact mechanics of which have been the topic of debate,⁷ with
160 most using a nominal group technique in which all arguments are considered initially prior to
161 a ranking exercise.

162 <H1>DISCUSSION

163 Although the need for core outcome sets is clear, as an essential complement to clinical
164 practice guidelines, the challenges of developing these for European-wide use are
165 considerable. Apart from the challenges of time, language, cultural, and healthcare system
166 differences, there is the issue of who will fund the development of these core outcome sets,
167 as the platforms for the Delphi consensus phase and probably the consensus meetings
168 require financial support.

169 Considerable time must be allowed to gain the necessary ethical and regulatory
170 approval for all participating centres. This is exacerbated by the study design being
171 somewhat novel (a survey involving patients, their relatives, industry, and clinicians), with
172 many processes not streamlined for such a design. The time and energy required to set up a
173 core outcome study is not dissimilar to that of a multicentre randomised trial. An example of
174 these delays is the Abdominal Aortic Aneurysm Core Outcome Set (AAA COS) project,
175 which registered back in 2020 with the Delphi survey due to go live two years later.⁸ This is
176 to be included in the 2024 AAA guideline renewal and therefore has received some support
177 from the ESVS. Despite such challenges, the present authors encourage others to develop
178 the core outcome sets needed for vascular surgery and are willing to offer advice based on
179 their experience.

180 CONTRIBUTIONS

181 Matthew Machin: Conceptualisation and design of the work, drafting and revising of the
182 article, final approval of the submitted version, and agreement to be accountable for all

183 factual aspects of the work and for ensuring that questions related to the accuracy or
184 integrity of any part of the work are appropriately investigated and resolved. Janet Powell:
185 Conceptualisation and design of the work, critical revision and writing of the article, final
186 approval of the submitted version, and agreement to be accountable for all factual aspects of
187 the work and for ensuring that questions related to the accuracy or integrity of any part of the
188 work are appropriately investigated and resolved.

189 **FUNDING**

190 None.

191 **CONFLICT OF INTEREST**


192 None.

193 **REFERENCES**

- 194 1. Machin M, Ulug P, Pandirajan K, Bown MJ, Powell JT. Towards a core outcome set
195 for abdominal aortic aneurysm: systematic review of outcomes reported following intact and
196 ruptured abdominal aortic aneurysm repair. *Eur J Vasc Endovasc Surg* 2021;**61**:909–18.
- 197 2. Ambler GK, Brookes-Howell L, Jones JA, Verma N, Bosanquet DC, Thomas-Jones
198 E, et al. Development of core outcome sets for people undergoing major lower limb
199 amputation for complications of peripheral vascular disease. *Eur J Vasc Endovasc Surg*
200 2020;**60**:730–8.
- 201 3. Williamson PR, Altman DG, Bagley H, Barnes KL, Blazeby JM, Brookes ST, et al.
202 The COMET handbook: version 1.0. *Trials* 2017;**18**:1–50.
- 203 4. Schiavo JH. PROSPERO: an international register of systematic review protocols.
204 *Med Ref Serv Q* 2019;**38**:171–80.
- 205 5. NIHR HTA. PPI (Patient and Public Involvement) resources for applicants to NIHR
206 research programmes 2022. Available at: <https://www.nihr.ac.uk/documents/> [Accessed 22
207 October 2022].
- 208 6. Dodd S, Clarke M, Becker L, Mavergames C, Fish R, Williamson PR. A taxonomy
209 has been developed for outcomes in medical research to help improve knowledge discovery.
210 *J Clin Epidemiol* 2018;**96**:84–92.
- 211 7. NHS Health Research Authority. Health Research Authority, What approvals and
212 decisions do I need? Available at: [https://www.hra.nhs.uk/approvals-amendments/what-
213 approvals-do-i-need/](https://www.hra.nhs.uk/approvals-amendments/what-approvals-do-i-need/) [Accessed 22 October 2022].
- 214 8. Powell JT. Development of a core outcome set for clinical studies reporting the
215 outcomes of patients undergoing repair of degenerative infrarenal abdominal aortic
216 aneurysms. Available at: <https://www.comet-initiative.org/Studies/Details/1582> [Accessed 22
217 October 2022].

218

219

220 **Figure 1.** Flowchart illustrating overview of developing a core outcome set.

221

222

223

224

225

226

227

